Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Kohrt, Holbrook E ^a   Tumeh, Paul C ^b   Benson, Don ^c   Bhardwaj, Nina ^d   Brody, Joshua ^d   Formenti, Silvia ^e   Fox, Bernard A ^f   Galon, Jerome ^g   June, Carl H ^h   Kalos, Michael ⁱ   Kirsch, Ilan ^j   Kleen, Thomas ^k   Kroemer, Guido ^l   Lanier, Lewis ^m   Levy, Ron ⁿ   Lyerly, H Kim ^o   Maecker, Holden ^p   Marabelle, Aurelien ^q   Melenhorst, Jos ^r   Miller, Jeffrey ^s   Melero, Ignacio ^t   Odunsi, Kunle ^u   Palucka, Karolina ^v   Peoples, George ^w   Ribas, Antoni ^x   Robins, Harlan ^y   Robinson, William ⁿ   Serafini, Tito ^z   Sondel, Paul ^aa   Vivier, Eric ^ab   Weber, Jeff ^ac   Wolchok, Jedd ^ad   Zitvogel, Laurence ^ae   Disis, Mary L ^af   Cheever, Martin A ^ag   more..

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j Adaptive Biotechnologies Corp   (United States)

^k EPIONTIS GMBH   (Germany)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p STANFORD CANCER INSTITUTE   (United States)

^q CENTRE LÉON BÉRARD   (France)

^r Institute for Translational Medicine and Therapeutics   (United States)

^s UNIVERSITY OF MINNESOTA   (United States)

^t UNIVERSITY OF NAVARRA   (Spain)

^u ROSWELL PARK CANCER INSTITUTE   (United States)

^v BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^w BROOKE ARMY MEDICAL CENTER   (United States)

^x UNIVERSITY OF CALIFORNIA   (United States)

^y ADAPTIVE BIOTECHNOLOGIES   (United States)

^z Atreca Inc   (United States)

^aa UNIVERSITY OF WISCONSIN MADISON   (United States)

^ab CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^ac H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^ad MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ae Institut GrustaveRoussy   (France)

^af UNIVERSITY OF WASHINGTON   (United States)

^ag USA   (United States)

more..

Author keywords

Biomarker; Clinical trial; Immunotherapy

Indexed keywords

C REACTIVE PROTEIN; CD3 ANTIBODY; CD7 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; DENDRITIC CELL VACCINE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; IPILIMUMAB; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; BIOPSY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; NEOPLASM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84997217016     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0118-0     Document Type: Review

References (124)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY). 2006;313(5795):1960-4. doi: 10.1126/science.1129139.
3. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):610-8. doi: 10.1200/jco.2010.30.5425.
4. Broussard EK, Disis ML. TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(6):601-3. doi: 10.1200/jco.2010.32.9078.
5. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306. doi: 10.1038/nrc3245.
6. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205. doi: 10.1186/1479-5876-10-205.
7. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199-209. doi: 10.1002/path.4287.
8. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery. 2011;1(1):54-67. doi: 10.1158/2159-8274.cd-10-0028.
9. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med. 2013;11:54. doi: 10.1186/1479-5876-11-54.
10. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9:214. doi: 10.1186/1479-5876-9-214.
11. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nature Reviews Immunol. 2009;9(5):353-63. doi: 10.1038/nri2545.
12. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol. 2004;84:131-79. doi: 10.1016/s0065-2776(04)84004-5.
13. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-60. doi: 10.1038/nrclinonc.2010.223.
14. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691-701. doi: 10.1084/jem.20050915.
15. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012;4(143):143ra99. doi: 10.1126/scitranslmed.3003807.
16. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28(5):578-90. doi: 10.1038/emboj.2009.1.
17. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011;208(3):491-503. doi: 10.1084/jem.20100269.
18. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nature Med. 2009;15(10):1170-8. doi: 10.1038/nm.2028.
19. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392(6671):86-9. doi: 10.1038/32183.
20. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science (New York, NY). 1995;267(5203):1456-62.
21. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (New York, NY). 2011;334(6062):1573-7. doi: 10.1126/science.1208347.
22. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482-91. doi: 10.1038/onc.2009.356.
23. Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G. Immunosurveillance against cancer-associated hyperploidy. Oncotarget. 2012;3(11):1270-1.
24. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21(1):69-78. doi: 10.1038/cdd.2013.72.
25. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, et al. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy. 2012;8(8):1175-84. doi: 10.4161/auto.20353.
26. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunol. 2014;3:e28518. doi: 10.4161/onci.28518.
27. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31. doi: 10.1056/NEJMoa1112824.
28. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256-65. doi: 10.1093/jnci/djs629.
29. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353-62. doi: 10.1158/1078-0432.ccr-04-2062.
30. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends in Immunol. 2008;29(6):256-62. doi: 10.1016/j.it.2008.03.002.
31. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365-72. doi: 10.1158/2326-6066.cir-13-0115.
32. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012;122(10):3718-30. doi: 10.1172/jci61931.
33. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734-8. doi: 10.1038/nature01112.
34. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006;103(24):9190-5. doi: 10.1073/pnas.0603503103.
35. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186-90. doi: 10.1038/nature03884.
36. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002.
37. Melenhorst JJ, Levine BL. Innovation and opportunity for chimeric antigen receptor targeted T cells. Cytotherapy. 2013;15(9):1046-53. doi: 10.1016/j.jcyt.2013.02.007.
38. Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257(1):14-38. doi: 10.1111/imr.12136.
39. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.
40. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-33. doi: 10.1056/NEJMoa1103849.
41. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18. doi: 10.1056/NEJMoa1215134.
42. Kalos M. Biomarkers in T cell therapy clinical trials. J Transl Med. 2011;9:138. doi: 10.1186/1479-5876-9-138.
43. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112-20. doi: 10.1158/2326-6066.cir-13-0170.
44. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
45. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9. doi: 10.1182/blood-2007-09-077438.
46. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (New York, NY). 2011;331(6013):44-9. doi: 10.1126/science.1198687.
47. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239-52. doi: 10.1038/nri3174.
48. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7. doi: 10.1182/blood-2004-07-2974.
49. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107. doi: 10.3109/14653249.2010.515582.
50. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59(11):1739-44. doi: 10.1007/s00262-010-0896-z.
51. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013;19(14):3844-55. doi: 10.1158/1078-0432.ccr-13-0505.
52. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123(19):3016-26. doi: 10.1182/blood-2013-10-533398.
53. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-8.
54. Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol. 2012;91(5):715-21. doi: 10.1007/s00277-011-1369-y.
55. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(3):474-81. doi: 10.1200/jco.2005.06.059.
56. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(21):3940-7. doi: 10.1200/jco.2003.05.013.
57. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(11):1789-96. doi: 10.1200/jco.2007.14.8957.
58. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011;22(6):1302-7. doi: 10.1093/annonc/mdq585.
59. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc(gamma)RIIa-Fc(gamma)RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(7):1122-9. doi: 10.1200/jco.2008.18.0463.
60. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809-12. doi: 10.1182/blood-2008-10-185280.
61. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124(6):2668-82. doi: 10.1172/jci73014.
62. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858-72. doi: 10.1158/1078-0432.ccr-12-2426.
63. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 2014;515(7528):496-8. doi: 10.1038/515496a.
64. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. doi: 10.1038/nrc3239.
65. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65. doi: 10.1056/NEJMoa1200694.
66. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44. doi: 10.1056/NEJMoa1305133.
67. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. doi: 10.1056/NEJMoa1200690.
68. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5s):9002.
69. Topalian Z, Niklasson GA, Granqvist CG, Osterlund L. Spectroscopic study of the photofixation of SO2 on anatase TiO2 thin films and their oleophobic properties. ACS Appl Mater Interfaces. 2012;4(2):672-9. doi: 10.1021/am201253y.
70. Harvey BP, Gee RJ, Haberman AM, Shlomchik MJ, Mamula MJ. Antigen presentation and transfer between B cells and macrophages. Eur J Immunol. 2007;37(7):1739-51. doi: 10.1002/eji.200636452.
71. Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N, et al. MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity. Clin Cancer Res. 2014;20:A20.
72. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ, Juergens RA, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clinical Invest. 2014;32(5s):8024.
73. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5s):5010.
74. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5s):5009.
75. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-7. doi: 10.1038/nature14011.
76. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl JMed. 2015;372(4):311-9. doi: 10.1056/NEJMoa1411087.
77. Seiwert TY, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5s):6011.
78. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li XN, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(5s):3002.
79. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-62. doi: 10.1038/nature13904.
80. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, NY). 2013;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.
81. Riley JL. Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med. 2013;369(2):187-9. doi: 10.1056/NEJMe1305484.
82. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71. doi: 10.1038/nature13954.
83. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008.
84. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711-9. doi: 10.1038/nrclinonc.2011.122.
85. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-95. doi: 10.1016/j.immuni.2013.10.003.
86. Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods (San Diego, Calif). 2014;70(1):46-58. doi: 10.1016/j.ymeth.2014.08.016.
87. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines. 2010;9(6):555-65. doi: 10.1586/erv.10.55.
88. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011;23(2):286-92. doi: 10.1016/j.coi.2010.11.013.
89. Robins H. Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol. 2013;25(5):646-52. doi: 10.1016/j.coi.2013.09.017.
90. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697-703. doi: 10.1093/annonc/mdt027.
91. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111(12):2214-9. doi: 10.1038/bjc.2014.348.
92. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116(7):1767-75. doi: 10.1002/cncr.24951.
93. Postow MA, Yuan J, Panageas KS, Bogatch K, Callahan MK, Cheng M, et al. Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3 mg/kg). J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(Suppl):8575.
94. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20:1747.
95. Bast Jr RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290(26):1458-69. doi: 10.1056/nejm197406272902605.
96. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008;358(14):1465-73. doi: 10.1056/NEJMoa072685.
97. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(28):4324-32. doi: 10.1200/jco.2010.28.9793.
98. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012;119(2):355-63. doi: 10.1182/blood-2011-05-355222.
99. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nature Med. 2013;19(3):329-36. doi: 10.1038/nm.3089.
100. Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y, Vanderwalde AM, Coffin R, Kaufman H. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GMCSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31:abstr LBA9008.
101. Disis ML, Dang Y, Coveler AL, Marzbani E, Kou ZC, Childs JS, et al. HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother. 2014;63(2):101-9. doi: 10.1007/s00262-013-1489-4.
102. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59(5):663-74. doi: 10.1007/s00262-009-0782-8.
103. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410-5. doi: 10.1073/pnas.0810114105.
104. Slota M, Lim JB, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011;10(3):299-306. doi: 10.1586/erv.10.169.
105. Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Molecular Biol (Clifton, NJ). 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15.
106. Mori A, Deola S, Xumerle L, Mijatovic V, Malerba G, Monsurro V. Next generation sequencing: new tools in immunology and hematology. Blood Res. 2013;48(4):242-9. doi: 10.5045/br.2013.48.4.242.
107. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003;9(3):998-1008.
108. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2(9):e284. doi: 10.1371/journal.pmed.0020284.
109. Chang AY, Bhattacharya N, Mu J, Setiadi AF, Carcamo-Cavazos V, Lee GH, et al. Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med. 2013;11:242. doi: 10.1186/1479-5876-11-242.
110. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nature Med. 2003;9(11):1377-82. doi: 10.1038/nm942.
111. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004;1(2):e28. doi: 10.1371/journal.pmed.0010028.
112. Kohrt HE, Shu CT, Stuge TB, Holmes SP, Weber J, Lee PP. Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J Immunother (Hagerstown, Md: 1997). 2005;28(4):297-305.
113. Emerson RO, Sherwood AM, Rieder MJ, Guenthoer J, Williamson DW, Carlson CS, et al. High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol. 2013;231(4):433-40. doi: 10.1002/path.4260.
114. Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, et al. Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol. 2013;231(4):424-32. doi: 10.1002/path.4284.
115. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205-9. doi: 10.1056/nejm199110243251703.
116. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunol. 2013;2(6):e24612. doi: 10.4161/onci.24612.
117. Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene therapy. Methods Molecular Biol (Clifton, NJ). 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.
118. Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol. 2005;6:17. doi: 10.1186/1471-2172-6-17.
119. Kalos M. An integrative paradigm to impart quality to correlative science. J Transl Med. 2010;8:26. doi: 10.1186/1479-5876-8-26.
120. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191-200. doi: 10.1038/nri3158.
121. Keustermans GC, Hoeks SB, Meerding JM, Prakken BJ, de Jager W. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods (San Diego, Calif). 2013;61(1):10-7. doi: 10.1016/j.ymeth.2013.04.005.
122. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med. 2011;3(108):108ps44. doi: 10.1126/scitranslmed.3002785.
123. Maecker HT, McCoy Jr JP, Amos M, Elliott J, Gaigalas A, Wang L, et al. A model for harmonizing flow cytometry in clinical trials. Nature Immunol. 2010;11(11):975-8. doi: 10.1038/ni1110-975.
124. Taylor CF, Field D, Sansone SA, Aerts J, Apweiler R, Ashburner M, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nature Biotechnol. 2008;26(8):889-96. doi: 10.1038/nbt.1411.